サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1623526

PGT（着床前遺伝学的検査）市場：製品タイプ別、サイクルタイプ別、技術別、手技タイプ別、用途別、エンドユーザー別、地域別、2024年～2031年

Preimplantation Genetic Testing Market By Product, By Cycle Type, By Technology, By Procedure Type, By Application, By End-User, And Region for 2024- 2031

出版日
ページ情報
英文 202 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
PGT（着床前遺伝学的検査）市場：製品タイプ別、サイクルタイプ別、技術別、手技タイプ別、用途別、エンドユーザー別、地域別、2024年～2031年
出版日: 2024年10月07日
発行: Verified Market Research
ページ情報: 英文 202 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

PGT（着床前遺伝学的検査）市場の評価-2024-2031

生殖補助医療技術（ART）に対する認識と利用の高まりは、遺伝子異常や不妊の懸念の増加とともに、PGT（着床前遺伝学的検査）市場を促進しています。Verified Market Researchのアナリストによると、PGT（着床前遺伝学的検査）市場は、2023年の評価額6億2,191万米ドルを下回る予測で、2031年には13億3,409万米ドルの評価額に達すると推定されます。

次世代シーケンシング（NGS）やアレイ比較ゲノムハイブリダイゼーション（aCGH）などのゲノム技術の進歩により、より正確で包括的な遺伝子スクリーニングが可能になり、市場の成長が加速しています。これにより、市場は2024年から2031年にかけてCAGR 10.01％で成長します。

PGT（着床前遺伝学的検査）市場定義／概要

PGT（着床前遺伝学的検査）（PGT）は、体外受精（IVF）により作製された胚に対する専門的な遺伝子検査プロセスです。子宮に入れられる前に、各胚から1つまたは数個の細胞を生検し、遺伝的構成を決定します。PGTは主に、胚の遺伝子異常、染色体異常、または特定の遺伝子変異を発見するために使用されます。

さらに、この方法は、遺伝性疾患を受け継ぐ危険性のあるカップル、反復性妊娠損失や体外受精の失敗の既往歴のある人、不妊治療を希望する高齢の女性に特に有用です。PGTは、遺伝性疾患のない胚を選択することを可能にし、妊娠の成功と健康な子供の誕生の可能性を高める。

PGT（着床前遺伝学的検査）市場の成長に影響を与える促進要因は？

遺伝子検査は、受精卵の早い段階で遺伝子の異常や病気を発見する利点が理解され、一般の人々の間で人気を集めています。このような意識は、特に遺伝性疾患の既往歴のある夫婦や、母親の年齢が高い夫婦、あるいは何度か妊娠に失敗した経験のある夫婦の間で、健康な赤ちゃんを望む傾向が高まっていることに伴っています。将来の世代の健康と幸福を守りたいというこの願望は、PGT（着床前遺伝学的検査）（PGT）を確立する重要な推進力となっています。

PGT（着床前遺伝学的検査）市場は、次世代シーケンシング（NGS）、ポリメラーゼ連鎖反応（PCR）、マイクロアレイ法などの遺伝子検査技術の進歩から大きな利益を得ています。これらの技術は遺伝子検査の精度、効率、スピードを向上させ、PGTをより身近で信頼できるものにしました。さらに、体外受精の機器や手順の進歩は、こうした遺伝子検査の改善をサポートし、不妊治療にPGTを組み込むことを容易にしています。

さらに、遺伝性疾患の世界の有病率は、診断方法の改善や認知度の向上もあって増加しています。家族に遺伝的問題があることが分かっているカップルや、原因不明の不妊症、流産、死産を経験したカップルは、子供に遺伝的異常が移る可能性を低くするためにPGTを選択する可能性が高くなっています。このような世代間の動向は、PGTサービスの潜在的な消費者層を広げ、市場の成長をもたらします。

倫理的懸念はPGT（着床前遺伝学的検査）の採用を抑制するか？

PGT（着床前遺伝学的検査）（PGT）とは、体外受精による妊娠の前に、胚に遺伝的問題がないかどうかを評価するプロセスです。これは、遺伝的特徴に基づいて胚を選択することについての倫理的懸念を提起し、"デザイナーベビー"につながる可能性があります。主要な遺伝的疾患を回避するためにPGTを利用することと、望ましい特徴を選択することとの間には狭い境界線があり、優生学、不公正、偏見に関する社会的、道徳的、倫理的懸念が生じ、それによって市場の成長が制限されます。

PGT技術は飛躍的な進歩を遂げたが、精度、効率、幅広い遺伝性疾患を検出する能力という点ではまだ限界があります。偽陽性や偽陰性が発生し、その結果、生存可能な胚が破壊されたり、未診断の遺伝子異常を持つ胚が選別されたりします。PGTの精度と範囲を向上させるには、継続的な研究開発が必要であり、それには費用と時間がかかるため、市場の拡大には限界があります。

目次

第1章 世界のPGT（着床前遺伝学的検査）市場：イントロダクション

  • 市場概要
  • 調査範囲
  • 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

  • データマイニング
  • バリデーション
  • 一次資料
  • データソース一覧

第4章 PGT（着床前遺伝学的検査）の世界市場展望

  • 概要
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • ポーターのファイブフォースモデル
  • バリューチェーン分析
  • 規制の枠組み

第5章 PGT（着床前遺伝学的検査）の世界市場：製品別

  • 概要
  • 試薬と消耗品
  • 検査機器
  • ソフトウェアとサービス

第6章 PGT（着床前遺伝学的検査）の世界市場：周期タイプ別

  • 概要
  • 新鮮非ドナー
  • 冷凍非ドナー
  • 新鮮ドナー
  • 凍結ドナー

第7章 PGT（着床前遺伝学的検査）の世界市場、技術別

  • 概要
  • 次世代シーケンシング（NGS）
  • ポリメラーゼ連鎖反応（PCR）
  • 蛍光in situハイブリダイゼーション
  • 比較ゲノムハイブリダイゼーション
  • 一塩基多型

第8章 PGT（着床前遺伝学的検査）の世界市場：手技タイプ別

  • 概要
  • 着床前遺伝子スクリーニング
  • 着床前遺伝子診断

第9章 PGT（着床前遺伝学的検査）の世界市場：用途別

  • 概要
  • 異数性
  • 構造的染色体異常
  • 単一遺伝子異常
  • X連鎖性疾患
  • HLAタイピング
  • 性別識別

第10章 PGT（着床前遺伝学的検査）の世界市場：エンドユーザー別

  • 概要
  • 不妊治療クリニック
  • 病院
  • 診断研究所
  • その他のエンドユーザー

第11章 PGT（着床前遺伝学的検査）の世界市場、地域別

  • 概要
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • その他欧州
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • その他アジア太平洋地域
  • 世界のその他の地域
    • ラテンアメリカ
    • 中東・アフリカ

第12章 世界のPGT（着床前遺伝学的検査）市場の競合情勢

  • 概要
  • 企業市場シェア
  • ベンダー情勢
  • 主な開発戦略

第13章 企業プロファイル

  • Illumina, Inc.
  • Thermo Fisher Scientific Inc.
  • Agilent Technologies, Inc.
  • Perkinelmer, Inc.
  • Coopersurgical, Inc.
  • Abbott Laboratories
  • Natera, Inc.
  • Rubicon Genomics
  • Oxford Gene Technology
  • Yikon Genomics
  • Scigene
  • Beijing Genomics Institute
  • Good Start Genetics
  • Invicta Genetics
  • Combimatrix
  • Genea Limited
  • Progenesis

第14章 付録

  • 関連レポート
目次
Product Code: 24037

Preimplantation Genetic Testing Market Valuation - 2024-2031

The growing awareness and use of assisted reproductive technologies (ART), along with increased occurrences of genetic abnormalities and infertility concerns, is propelling the preimplantation genetic testing (PGT) market. According to the analyst from Verified Market Research, the Preimplantation Genetic Testing Market is estimated to reach a valuation of USD 1334.09 Million in 2031 over the forecast subjugating around USD 621.91 Million valued in 2023.

Advancements in genomic technologies, such as next-generation sequencing (NGS) and array comparative genomic hybridization (aCGH), are allowing for more precise and comprehensive genetic screening, accelerating market growth. It enables the market to grow at a CAGR of 10.01% from 2024 to 2031.

Preimplantation Genetic Testing Market: Definition/Overview

Preimplantation Genetic Testing (PGT) is a specialized genetic testing process for embryos generated through in vitro fertilization (IVF). Before being put into the uterus, one or a few cells from each embryo are biopsied to determine their genetic makeup. PGT is primarily used to discover genetic abnormalities, chromosomal problems, or specific genetic mutations in embryos, allowing prospective parents to make educated decisions about embryo selection for implantation.

Furthermore, this method is especially useful for couples at risk of passing on genetic illnesses, individuals with a history of recurrent pregnancy loss or unsuccessful IVF attempts, and older women seeking fertility treatments. PGT allows for the selection of embryos free of genetic diseases, boosting the chances of a successful pregnancy and the birth of a healthy child.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Which are the Drivers Influencing the Growth of the Preimplantation Genetic Testing Market?

Genetic testing is gaining popularity among the general public, owing to a better understanding of its benefits in detecting genetic abnormalities and ailments early in the embryonic stage. This awareness is accompanied by a rising preference for healthy babies, particularly among couples with a history of genetic diseases, those of advanced maternal age, or those who have experienced several pregnancy losses. This desire to protect future generations' health and well-being is an important driver to establishing preimplantation genetic testing (PGT).

The Preimplantation Genetic Testing Market has profited greatly from advances in genetic testing technologies such as Next Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), and Microarray methods. These technologies have increased the accuracy, efficiency, and speed of genetic testing, making PGT more accessible and dependable. Furthermore, advances in IVF equipment and procedures support these genetic testing improvements, making it easier to incorporate PGT into fertility treatments.

Furthermore, the global prevalence of genetic illnesses is increasing, owing in part to improved diagnosis procedures and more awareness. Couples with known genetic problems in their families, as well as those who have had unexplained infertility, miscarriages, or stillbirths, are more likely to choose PGT to lower the possibility of transferring genetic abnormalities to their children. This generational trend broadens the potential consumer base for PGT services, resulting in market growth.

Will Ethical Concerns Restrain Adoption of Preimplantation Genetic Testing?

Preimplantation genetic testing (PGT) is the process of evaluating embryos for genetic problems before to pregnancy using in vitro fertilization. This raises ethical concerns about selecting embryos based on genetic features, which might lead to "designer babies." There is a narrow line between utilizing PGT to avoid major genetic illnesses and choosing desirable features, which creates social, moral, and ethical concerns about eugenics, injustice, and prejudice, thereby limiting market growth.

While PGT technologies have made tremendous advances, they still have limits in terms of accuracy, efficiency, and capacity to detect a wide spectrum of genetic disorders. False positives or negatives occur, resulting in the destruction of viable embryos or the selection of embryos with undiagnosed genetic abnormalities. Improving the accuracy and scope of PGT necessitates continual research and development, which is expensive and time-consuming, limiting market expansion.

Category-wise Acumens

How does the Dominance of the Reagents and Consumables Impact the Market?

According to VMR analyst, the reagents and consumables segment is anticipated to dominate the segment within the Preimplantation Genetic Testing Market. Reagents and consumables are required at all stages of the PGT process, from DNA amplification to analysis. These items are used in big quantities and require regular replenishment, resulting in a steady demand. Unlike instruments, which are long-term capital investments, reagents and consumables are continuing operating expenses for genetic testing laboratories. This large volume utilization greatly increases their market share.

The field of genetic testing, including PGT, is quickly growing, with ongoing advances and breakthroughs in reagents and consumables. These advancements have the potential to improve the accuracy, speed, and efficiency of testing processes. Also, the flexibility to tailor reagents and consumables to specific tests or conditions helps accelerate their adoption, addressing the precise requirements of PGT laboratories and clinics.

Furthermore, reagents and consumables are used in a variety of PGT procedures, including Preimplantation Genetic Screening (PGS) for aneuploidy detection, Preimplantation Genetic Diagnosis (PGD) for single gene diseases, and newer approaches for structural rearrangements and mitochondrial illnesses. These products' market domination is due to their adaptability and requirement in a variety of PGT applications.

How does the Rising Awareness of Genetic Disorders Contribute to the PGD Segment?

The preimplantation genetic diagnosis (PGD) segment is estimated to hold the largest share of the Preimplantation Genetic Testing Market during the forecast period. PGD is utilized specifically by couples who are known to have a high chance of passing on specific genetic disorders to their children. This specialized approach to testing detects single-gene disorders and chromosomal anomalies unique to the parents' genetic origins, making it an essential tool for families looking to avoid the transfer of hereditary diseases. The need for PGD stems from its capacity to bring peace of mind to at-risk couples by ensuring the birth of healthy offspring free of specific genetic abnormalities.

Furthermore, the general public and healthcare professionals are becoming increasingly aware of the benefits of genetic testing in preventing inherited disorders. This awareness, combined with the rising occurrence of genetic abnormalities due to a variety of reasons, including longer parental ages at conception, has resulted in increased demand for PGD. Prospective parents are becoming more knowledgeable and proactive about their reproductive options, resulting in an increase in the use of PGD to assure the health and well-being of their future offspring.

Country/Region-wise Acumens

How will Demand for Preimplantation Genetic Testing Shape the North American Market?

According to VMR analysis, the North American region is estimated to dominate in Preimplantation Genetic Testing Market during the forecast period. Genetic testing and its benefits are widely understood and accepted in North America. This is due in part to healthcare providers' educational efforts, patient group activism, and media and popular culture coverage. As a result, there is a high demand for genetic testing services, including PGT, among people and couples seeking to uncover genetic abnormalities, assess risks to future children, and make educated reproductive decisions. This desire is amplified by the cultural acceptance of IVF and related reproductive technologies.

Furthermore, North America, particularly the United States, has some of the world's most advanced healthcare infrastructure, with cutting-edge medical facilities, leading-edge research institutions, and a strong emphasis on new healthcare solutions. This infrastructure facilitates considerable research and development efforts in genetic testing and reproductive technologies. Furthermore, substantial healthcare expenditure in the region, both public and private, allows for significant investment in new technology and treatments, making modern PGT services broadly available to patients.

Will the Asia Pacific prove Opportunistic for the Preimplantation Genetic Testing Market?

Asia Pacific is estimated to grow at the highest CAGR in the Preimplantation Genetic Testing Market. This region has experienced substantial growth in awareness and acceptance of genetic testing and its potential advantages. This is attributable to improved knowledge, more access to information via digital platforms, and government-led initiatives to promote genetic health. As a result, more people and couples are using PGT as part of their family planning, increasing market demand.

Furthermore, governments around Asia Pacific are making significant investments in healthcare infrastructure as well as encouraging biotechnology and genetic engineering research. Countries such as China, Japan, South Korea, and Singapore are setting the standard for enacting policies that encourage the adoption of modern medical technology, including PGT. These measures, combined with supporting legislative frameworks, are considerably boosting the region's PGT market.

Competitive Landscape

The competitive landscape of the preimplantation genetic testing (PGT) market is marked by a constant interplay of technology breakthroughs, regulatory frameworks, and shifting customer preferences. Furthermore, cooperation among healthcare providers, research institutions, and technology companies are pushing innovation and broadening the use of PGT beyond typical genetic disorders to include broader genomic profiling.

Some of the prominent players operating in the Preimplantation Genetic Testing Market include:

Illumina, Inc., Thermo Fisher Scientific Inc., Agilent Technologies, Inc., PerkinElmer Inc., CooperSurgical, Abbott Laboratories, Natera, Rubicon Genomics, Oxford Gene Technology, Yikon Genomics, Scigene, Beijing Genomics Institute, Good Start Genetics, Invicta Genetics, Combimatrix, Genea Limited, Progenesis, Igenomix.

Latest Developments:

In April 2023, Eurofins Genoma, a leader in the PGT market, launched niPGT-A, a non-invasive preimplantation genetic aneuploidy screening test. This new test analyses cell-free foetal DNA in the maternal bloodstream, providing a less intrusive option for couples undergoing in vitro fertilization (IVF).

In April 2023, LifeView, powered by Genomic Prediction, announced a partnership with Ovation Fertility. This agreement gives Ovation patients access to the LifeView PGT Platform, which provides cutting-edge technology and might significantly improve their clinical care experience.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL PREIMPLANTATION GENETIC TESTING MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL PREIMPLANTATION GENETIC TESTING MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis
  • 4.5 Regulatory Framework

5 GLOBAL PREIMPLANTATION GENETIC TESTING MARKET, BY PRODUCT

  • 5.1 Overview
  • 5.2 Reagents and Consumables
  • 5.3 Instruments
  • 5.4 Software and Services

6 GLOBAL PREIMPLANTATION GENETIC TESTING MARKET, BY CYCLE TYPE

  • 6.1 Overview
  • 6.2 Fresh Non-donor
  • 6.3 Frozen Non-donor
  • 6.4 Fresh Donor
  • 6.5 Frozen Donor

7 GLOBAL PREIMPLANTATION GENETIC TESTING MARKET, BY TECHNOLOGY

  • 7.1 Overview
  • 7.2 Next-generation Sequencing (NGS)
  • 7.3 Polymerase Chain Reaction (PCR)
  • 7.4 Fluorescence In Situ Hybridization
  • 7.5 Comparative Genomic Hybridization
  • 7.6 Single-nucleotide Polymorphism

8 GLOBAL PREIMPLANTATION GENETIC TESTING MARKET, BY PROCEDURE TYPE

  • 8.1 Overview
  • 8.2 Preimplantation Genetic Screening
  • 8.3 Preimplantation Genetic Diagnosis

9 GLOBAL PREIMPLANTATION GENETIC TESTING MARKET, BY APPLICATION

  • 9.1 Overview
  • 9.2 Aneuploidy
  • 9.3 Structural Chromosomal Abnormalities
  • 9.4 Single Gene Disorders
  • 9.5 X-linked Disorders
  • 9.6 HLA Typing
  • 9.7 Gender Identification

10 GLOBAL PREIMPLANTATION GENETIC TESTING MARKET, BY END-USER

  • 10.1 Overview
  • 10.2 Fertility Clinics
  • 10.3 Hospitals
  • 10.4 Diagnostic Laboratories
  • 10.5 Other End Users

11 GLOBAL PREIMPLANTATION GENETIC TESTING MARKET, BY GEOGRAPHY

  • 11.1 Overview
  • 11.2 North America
    • 11.2.1 U.S.
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 U.K.
    • 11.3.3 France
    • 11.3.4 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 China
    • 11.4.2 Japan
    • 11.4.3 India
    • 11.4.4 Rest of Asia Pacific
  • 11.5 Rest of the World
    • 11.5.1 Latin America
    • 11.5.2 Middle East and Africa

12 GLOBAL PREIMPLANTATION GENETIC TESTING MARKET COMPETITIVE LANDSCAPE

  • 12.1 Overview
  • 12.2 Company Market Share
  • 12.3 Vendor Landscape
  • 12.4 Key Development Strategies

13 COMPANY PROFILES

  • 13.1 Illumina, Inc.
    • 13.1.1 Overview
    • 13.1.2 Financial Performance
    • 13.1.3 Product Outlook
    • 13.1.4 Key Developments
  • 13.2 Thermo Fisher Scientific Inc.
    • 13.2.1 Overview
    • 13.2.2 Financial Performance
    • 13.2.3 Product Outlook
    • 13.2.4 Key Developments
  • 13.3 Agilent Technologies, Inc.
    • 13.3.1 Overview
    • 13.3.2 Financial Performance
    • 13.3.3 Product Outlook
    • 13.3.4 Key Developments
  • 13.4 Perkinelmer, Inc.
    • 13.4.1 Overview
    • 13.4.2 Financial Performance
    • 13.4.3 Product Outlook
    • 13.4.4 Key Developments
  • 13.5 Coopersurgical, Inc.
    • 13.5.1 Overview
    • 13.5.2 Financial Performance
    • 13.5.3 Product Outlook
    • 13.5.4 Key Developments
  • 13.6 Abbott Laboratories
    • 13.6.1 Overview
    • 13.6.2 Financial Performance
    • 13.6.3 Product Outlook
    • 13.6.4 Key Developments
  • 13.7 Natera, Inc.
    • 13.7.1 Overview
    • 13.7.2 Financial Performance
    • 13.7.3 Product Outlook
    • 13.7.4 Key Developments
  • 13.8 Rubicon Genomics
    • 13.8.1 Overview
    • 13.8.2 Financial Performance
    • 13.8.3 Product Outlook
    • 13.8.4 Key Developments
  • 13.9 Oxford Gene Technology
    • 13.9.1 Overview
    • 13.9.2 Financial Performance
    • 13.9.3 Product Outlook
    • 13.9.4 Key Developments
  • 13.10 Yikon Genomics
    • 13.10.1 Overview
    • 13.10.2 Financial Performance
    • 13.10.3 Product Outlook
    • 13.10.4 Key Developments
  • 13.11 Scigene
    • 13.11.1 Overview
    • 13.11.2 Financial Performance
    • 13.11.3 Product Outlook
    • 13.11.4 Key Developments
  • 13.12 Beijing Genomics Institute
    • 13.12.1 Overview
    • 13.12.2 Financial Performance
    • 13.12.3 Product Outlook
    • 13.12.4 Key Developments
  • 13.13 Good Start Genetics
    • 13.13.1 Overview
    • 13.13.2 Financial Performance
    • 13.13.3 Product Outlook
    • 13.13.4 Key Developments
  • 13.14 Invicta Genetics
    • 13.14.1 Overview
    • 13.14.2 Financial Performance
    • 13.14.3 Product Outlook
    • 13.14.4 Key Developments
  • 13.15 Combimatrix
    • 13.15.1 Overview
    • 13.15.2 Financial Performance
    • 13.15.3 Product Outlook
    • 13.15.4 Key Developments
  • 13.16 Genea Limited
    • 13.16.1 Overview
    • 13.16.2 Financial Performance
    • 13.16.3 Product Outlook
    • 13.16.4 Key Developments
  • 13.17 Progenesis
    • 13.17.1 Overview
    • 13.17.2 Financial Performance
    • 13.17.3 Product Outlook
    • 13.17.4 Key Developments

14 Appendix

  • 14.1 Related Reports